Notable Analyst Rating Changes 6/30: (BCRX) (ING) (RRC) Upgraded; (NI) (APOL) (ANF) Downgraded
Tweet Send to a Friend
UPGRADES
BofA/Merrill Lynch boosts BioCryst Pharma (Nasdaq: BCRX) from Neutral to Buy boosts its price target from $12 up to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BofA/Merrill Lynch boosts BioCryst Pharma (Nasdaq: BCRX) from Neutral to Buy boosts its price target from $12 up to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
